Skip to content

Ketamine research published in 2025

Page 34 of 39: studies 661 to 680 of 780, newest first. Back to the ketamine overview

Studies

Repeated high-dose esketamine in early postnatal rats leads to behavioural deficits with long-term modifications in white matter microstructural integrity.

Brain Research January 15, 2025 Lijie Zhou, Xianlei Wang, Tianyu Cao et al. 4 citations

Esketamine is commonly used for sedation or general anaesthesia in infants and young children. However, repeated esketamine administration during periods of rapid brain growth and development may result in various pathophysiological and cognitive changes. Therefore, this study aimed to investigate the influence of recurrent esketamine exposure on long-term behavioural and white matter...

Cognitive and kinematic markers of ketamine effects in behaving non-human primates.

European Journal of Pharmacology January 15, 2025 Pierre Pouget, Pierre Daye, Martin Paré 2 citations

Ketamine is widely used to probe cognitive functions relying on the properties of methyl-D-aspartate receptor (NMDAR) synaptic transmission. Numerous works have proved that cognitive performance and adjustments in the decision or perceptual domains are affected after ketamine injection in general circulation of primates. Here, we take advantage of that in the brain stem; horizontal saccade...

Ketamine Infusion for Complex Regional Pain Syndrome Treatment: A Narrative Review.

Current Pain and Headache Reports January 14, 2025 Alan D. Kaye, Brynne E Tynes, Coplen D Johnson et al. 6 citations

Complex Regional Pain Syndrome (CRPS) is a neuropathic pain disorder characterized by pain disproportionate to the inciting event that is constant for an extended duration. Numerous treatment options for this condition have been explored with unsatisfactory results in many cases. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist typically used as an anesthetic and analgesic, presents...

DOI: 10.1007/s11916-025-01360-9 (opens in new tab) Full text (opens in new tab) Narrative review Pain management Ketamine therapy Crps treatment +2

Neurophysiological correlates of ketamine-induced dissociative state in bipolar disorder: insights from real-world clinical settings.

Molecular Psychiatry January 14, 2025 Claudio Agnorelli, Alessandra Cinti, Giovanni Barillà et al. 8 citations

Ketamine, a dissociative compound, shows promise in treating mood disorders, including treatment-resistant depression (TRD) and bipolar disorder (BD). Despite its therapeutic potential, the neurophysiological mechanisms underlying ketamine's effects are not fully understood. This study explored acute neurophysiological changes induced by subanesthetic doses of ketamine in BD patients with...

Efficacy of single and repeated ketamine administration for suicidal ideation in adults with psychiatric disorders: A meta-analysis.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Wanting Feng, Chengfeng Chen, Yexian Zeng et al. 9 citations

Previous studies have demonstrated rapid-onset anti-suicidal ideation effects of ketamine. This study aimed to compare the efficacy and duration of anti-suicidal thoughts following single- and repeated-dose ketamine administration. We retrieved published studies on ketamine for suicidal ideation (SI) from PubMed, OVID (MEDLINE), Web of Science, and Embase, spanning from inception to May 1,...

DOI: 10.1016/j.pnpbp.2024.111152 (opens in new tab) Full text (opens in new tab) Meta-analysis Suicidal ideation Ketamine therapy Suicide prevention +2

The immune regulatory mechanism of ketamine-induced psychiatric disorders: A new perspective on drug-induced psychiatric symptoms.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Peipei Wang, Junmei Hu, Congliang Chen et al. 2 citations

Ketamine, a psychoactive substance strictly regulated by international drug conventions, is classified as a "new type drug" due to its excitatory, hallucinogenic, or inhibitory effects. The etiology of ketamine-induced psychiatric symptoms is multifaceted, with the immune regulatory mechanism being the most prominent among several explanatory theories. In recent years, the interaction between...

DOI: 10.1016/j.pnpbp.2024.111194 (opens in new tab) Full text (opens in new tab) New drugs Ketamine therapy Neuroimmunology research Psychiatric treatment +2

Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Stefania Chiappini, Amira Guirguis, Nicolò Schifano et al. 12 citations

Intranasal esketamine, approved with oral antidepressants for adults with treatment-resistant depression (TRD), is the S-enantiomer of ketamine and has higher potency and affinity for N-Methyl-d-Aspartate receptors. Administered intranasally, it offers rapid absorption and onset, essential for severe depressive symptoms or suicidal impulses. Comparative studies on esketamine and ketamine's...

DOI: 10.1016/j.pnpbp.2024.111213 (opens in new tab) Full text (opens in new tab) S-ketamine Pharmacovigilance Urological safety Drug surveillance +5

Arketamine alleviates cognitive impairments and demyelination in mice with postoperative cognitive dysfunction via TGF-β1 activation.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Ting-Ting Zhu, Ming-Ming Zhao, Dan Xu et al. 5 citations

Postoperative cognitive dysfunction (POCD) is characterized by a decline in cognitive functions, including memory, attention, and executive abilities, following surgery, with no effective therapeutic drugs currently available. Arketamine, the (R)-enantiomer of ketamine, has shown promise in mitigating cognitive deficits in animal models. In this study, we investigated whether arketamine could...

DOI: 10.1016/j.pnpbp.2024.111228 (opens in new tab) Full text (opens in new tab) Arketamine Demyelination Postoperative cognitive dysfunction Surgery +5

Proteomic patterns associated with ketamine response in major depressive disorders.

Cell Biology and Toxicology January 10, 2025 Nan Zhou, Xiaolei Shi, Runhua Wang et al. 1 citation

Major depressive disorder (MDD) is characterized by persistent feelings of sadness and loss of interest. Ketamine has been widely used to treat MDD owing to its rapid effect in relieving depressive symptoms. Importantly, not all patients respond to ketamine treatment. Identifying sub-populations who will benefit from ketamine, as well as those who may not, prior to treatment initiation, would...

Additively manufactured ready-to-use platform using conductive recycled PLA for ketamine sensing.

Mikrochimica acta January 9, 2025 Maria M C Souza, Raquel G Rocha, Gilvana P Siqueira et al. 12 citations

The use of 3D-printed electrodes is reported fabricated from in-house conductive filament composed of a mixture of recycled poly (lactic acid) (rPLA), graphite (Gpt), and carbon black (CB) for fast detection of the abused drug ketamine. Firstly, the performance of these electrodes was evaluated in comparison to 3D-printed electrodes produced employing a commercially available conductive...

DOI: 10.1007/s00604-024-06902-3 (opens in new tab) Full text (opens in new tab) Beverage samples Circular economy Date rape drug Differential pulse voltammetry +8

Psychotic-Like Experiences in Young Recreational Users of Ketamine: A Case Study.

Journal of Psychoactive Drugs January 8, 2025 Valerio Ricci, Domenico de Berardis, Sheikh Shoib et al. 4 citations

This study explores the psychotic-like experiences (PLEs) associated with recreational ketamine use among young adults. Ketamine, initially introduced as an anesthetic, is now widely used recreationally for its dissociative effects, raising concerns about its impact on mental health. Ten participants aged 18-24, who used ketamine recreationally multiple times a week, were assessed using the...

DOI: 10.1080/02791072.2025.2449909 (opens in new tab) Full text (opens in new tab) Novel psychoactive drugs Psychotic-like symptoms Schizophrenia Ketamine abuse +3

Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study.

The British Journal of Psychiatry January 7, 2025 Natalie T Mills, Stevan Nikolin, Nick Glozier et al. 3 citations Retracted

Anxiety disorders and treatment-resistant major depressive disorder (TRD) are often comorbid. Studies suggest ketamine has anxiolytic and antidepressant properties. To investigate if subcutaneous racemic ketamine, delivered twice weekly for 4 weeks, reduces anxiety in people with TRD. The Ketamine for Adult Depression Study was a multisite 4-week randomised, double-blind, active...

DOI: 10.1192/bjp.2024.250 (opens in new tab) Full text (opens in new tab) #ketamine-therapy ketamine treatment Ketamine infusion #anxiety-depression mood disorders Mental health conditions +4

Ketamine-Assisted Psychotherapy for Antisocial Personality Disorder: A Case Report.

Journal of Psychoactive Drugs January 7, 2025 Matthew Hicks, Heather Zwickey, Ryan Bradley 2 citations

There are currently no evidence-based treatment guidelines for antisocial personality disorder (ASPD). Instead, treatment typically focuses on comorbid conditions. There is currently no literature documenting cases or research, theoretical or otherwise of using ketamine-assisted therapy or any other psychedelic therapy in cases of ASPD. In this case report, a 43-year-old man seeking...

DOI: 10.1080/02791072.2025.2449911 (opens in new tab) Full text (opens in new tab) Antisocial personality disorder Case report Ketamine-assisted psychotherapy Mental health treatment +2

Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study.

BMC Psychiatry January 7, 2025 Katelyn Halpape, Raelle Pashovitz, Annabelle Wanson et al. 4 citations

Ketamine is a promising therapy for treatment-resistant depression due to its rapid onset, although benefits are often transitory, with patients needing maintenance therapy to prevent relapse. Most data supporting ketamine for treatment-resistant depression refers to the intravenous route of administration, leaving alternative routes lacking in data, especially as maintenance regimens....

Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management.

Current Pain and Headache Reports January 7, 2025 Natalie H Strand, Madeline Whitney, Brooks Johnson et al. 9 citations

Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on healthcare systems. Conventional treatments, such as opioids and non-steroidal anti-inflammatory drugs, are frequently linked to adverse effects, including dependency and gastrointestinal issues, and often offer limited long-term relief. This review...

Effects of combined postweaning social isolation and ketamine administration on schizophrenia-like behaviour in male Sprague Dawley rats.

Behavioural Brain Research January 5, 2025 Khanyiso Bright Shangase, Mluleki Luvuno, Musa V Mabandla 6 citations

The pathophysiology behind negative and cognitive symptoms of schizophrenia is not well understood, thus limiting the effectiveness of treatment on these symptoms. Developing reliable animal model of schizophrenia is vital to advance our understanding on the neurobiological basis of the disorder. Double hit is used to refer to the use of two schizophrenia inducing interventions viz ketamine...

Cortical high-frequency oscillations (≈ 110 Hz) in cats are state-dependent and enhanced by a subanesthetic dose of ketamine.

Behavioural Brain Research January 5, 2025 Santiago Castro-Zaballa, Joaquín González, Matías Cavelli et al. 4 citations

Ketamine is an NMDA receptor antagonist that has antidepressant and anesthetic properties. At subanesthetic doses, ketamine induces transient psychosis in humans, and is used to model psychosis in experimental animals. In rodents, subanesthetic doses of ketamine increase the power of high-frequency oscillations (HFO, > 100 Hz) in the electroencephalogram (EEG), a frequency band linked to...

(2R, 6R)-hydroxynorketamine ameliorates PTSD-like behaviors during the reconsolidation phase of fear memory in rats by modulating the VGF/BDNF/GluA1 signaling pathway in the hippocampus.

Behavioural Brain Research January 5, 2025 Han Wang, Yuxuan He, Jiahao Tang et al. 5 citations

Fear memory, a fundamental symptom of post-traumatic stress disorder (PTSD), is improved by (2R, 6R)-hydroxynorketamine ((2R, 6R)-HNK) administration. However, the phase of fear memory in which the injected drug is the most effective at mitigating PTSD-like effects remains unknown. This study aimed to explore the effects of (2 R, 6 R)-HNK administration during three phases [acquisition (AP),...

DOI: 10.1016/j.bbr.2024.115273 (opens in new tab) Full text (opens in new tab) 2r 6r-hydroxynorketamine Acquisition Extinc-tion +6

The potential therapeutic effect of donepezil on a ketamine rat model of psychosis ‎

Journal of advanced pharmacy education and research 2025 K. Mehdar

Mental illnesses like bipolar disorder and schizophrenia often present psychotic symptoms. Current antipsychotic medications, including clozapine, can cause serious side effects. This study investigates the potential therapeutic effects of the cholinesterase inhibitor donepezil compared to clozapine in a ketamine-induced psychosis model in rats. Forty adult male albino rats were divided into...

Rebuilding the atrophied brain: 6-month nasal esketamine therapy expands key frontal and hippocampal regions and reduces serum neurofilament levels in patients with major depressive disorder. A proof-of-concept study of the depTesk (DEPression treatment with ESKetamine) study

CNS Spectrums 2025 Ana Rodríguez Lorente, María Pilar Campos-Navarro, Ángela Gil Montoya et al.

Abstract Objectives This proof-of-concept study aimed to assess the impact of intranasal esketamine (ESK-IN) in brain volume and neurofilament light chain (sNfL) over 6-months in patients with treatment resistant depression (TDR). Methods Seven TRD patients received ESK-IN while continuing oral antidepressants. Clinical evaluations were conducted at baseline, 1, 3, and 6 months, with MRI scans...